Hypersensitivity reactions
Few cases were reported: one with a morbiliform eruption and exfoliative
dermatitis due to ruxolitinib (156), another one with palmoplantar
pustulosis due to baricitinib (157), and cases of acute urticaria (158)
and palmoplantar pustulosis (159) due to tofacitinib.